Stockscreener 앱 받기
366.81
0.45%
-1.65
시간 외 거래:
366.81
Praxis Precision Medicines Inc 주식(PRAX)의 최신 뉴스
9,840 Shares in Praxis Precision Medicines, Inc. $PRAX Purchased by Handelsbanken Fonder AB - MarketBeat
PRAX Stock Drops 12% After Hours On Trial Setback — Retail Eyes FDA Approval Of Other Pipeline Candidates - Stocktwits
Praxis Precision Medicines (PRAX): Orbis, Allan Gray disclose 5.5% ownership stake - Stock Titan
(PRAX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Praxis (PRAX) Q2 2026 Earnings Call Transcript - AOL.com
Praxis Precision Medicines (NASDAQ:PRAX) Reaches New 12-Month HighHere's Why - MarketBeat
4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year - TradingView
Equities Analysts Offer Predictions for PRAX Q3 Earnings - MarketBeat
H.C. Wainwright Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $1,201 - moomoo.com
Weekly Recap: Cash runway into 2028 and RBC raises price target - TradingView
High Growth Tech Stocks in the US to Watch - simplywall.st
Dimensional Fund Advisors LP Has $10.04 Million Holdings in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines (PRAX) Wins FDA Breakthrough Tag As CNS Pipeline Advances - simplywall.st
Is Praxis (PRAX) Trading Bigger Losses for Long-Run CNS Ambition With Its Cash War Chest? - Yahoo Finance
LifeSci Capital Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $754 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $441 to $1,201 - Moomoo
Praxis Precision Medicines (NASDAQ:PRAX) Upgraded by Wall Street Zen to "Hold" Rating - marketbeat.com
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $462 to $800 - moomoo.com
JonesTrading Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $441 - Moomoo
Praxis: Commercial Launch Could Smash Expectations (Video) - Seeking Alpha
RBC Adjusts PT on Praxis Precision Medicines to $462 From $449, Keeps Outperform Speculative Risk Rating - Moomoo
Deutsche Bank Adjusts Praxis Precision Medicines PT to $475 From $374, Maintains Buy Rating - marketscreener.com
Praxis Precision Medicines, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Praxis Precision Medicines, Inc (PRAX): Investor Outlook on a Biotech Powerhouse with 71.91% Upside Potential - DirectorsTalk Interviews
Glenmede Trust Co. NA Sells 2,878 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines Q2 Earnings Call Highlights - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Releases Quarterly Earnings Results, Beats Estimates By $0.80 EPS - MarketBeat
PD Small-Cap Value Index Portfolio's Praxis Precision Medicines Inc(PRAX) Holding History - GuruFocus
Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Hi - GuruFocus
Wedbush Adjusts PT on Praxis Precision Medicines to $188 From $162, Maintains Underperform Rating - Moomoo
Form 8K Praxis Precision Medicines Inc For: 6 August By Investing.com - Investing.com Nigeria
Praxis Precision Medicines, Inc. Stock 12‑Month Price Target Raised to $620.95, Implies 95% Upside - TradingView
Praxis Precision Medicines stock hits 52-week high at 366.7 USD - Investing.com Nigeria
Praxis Precision Medicines Inc (PRAX) (Q2 2026) Earnings Call Highlights: FDA Approvals on ... - Yahoo Finance
Earnings call transcript: Praxis Precision Medicines beats Q2 2026 EPS forecast as shares jump - Investing.com Nigeria
PRAXIS PRECISION MEDICINES, INC. : RBC RAISES TARGET PRICE TO $462 FROM $449 - Bitget
PRAXIS PRECISION MEDICINES, INC. : BAIRD RAISES TARGET PRICE TO $514 FROM $400 - Bitget
Needham & Company LLC Raises Praxis Precision Medicines (NASDAQ:PRAX) Price Target to $582.00 - MarketBeat
Praxis Precision Medicines gains as investors refocus on late-stage CNS pipeline and upcoming FDA catalysts - Quiver Quantitative
Praxis Precision Medicines (NASDAQ:PRAX) Sets New 12-Month High Following Better-Than-Expected Earnings - marketbeat.com
Praxis Precision Medicines, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Praxis Precision Medicines Q2 Net Loss Narrows; Shares Up Pre-Bell - marketscreener.com
Earnings Flash (PRAX) Praxis Precision Medicines Posts Q2 Loss $2.87 a Share, vs. FactSet Est of $3.64 Loss - marketscreener.com
Praxis Precision Medicines beats Q2 loss estimates; shares rise By Investing.com - Investing.com South Africa
Praxis Precision Medicines beats Q2 loss estimates; shares rise - Investing.com
Praxis Precision Medicines Q2 2026: Net loss $(83.7M), EPS $(2.87) — 10-Q Summary - TradingView
Praxis Precision Medicines (NASDAQ: PRAX) holds $1.4B cash, advances NDAs - Stock Titan
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Resultsmoomoo - Moomoo
Q2 2026 Praxis Precision Medicines Inc Earnings Call Transcript - GuruFocus
Praxis Precision Medicines, Inc. $PRAX Stock Holdings Lifted by Bank of America Corp DE - MarketBeat
Praxis Precision earnings on deck as commercialization nears - Investing.com
California State Teachers Retirement System Increases Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
29 New Praxis Employees Get Stock Units, Four-Year Vesting - Stock Titan
Praxis Precision Medicines Inc expected to post a loss of $3.66 a shareEarnings Preview - TradingView
Praxis Precision Medicines, Inc. $PRAX Stock Position Boosted by Perceptive Advisors LLC - MarketBeat
Praxis Precision Medicines (PRAX) Projected to Announce Earnings on Monday - MarketBeat
Praxis Precision Medicines, Inc. $PRAX Position Increased by Vivo Capital LLC - MarketBeat
Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 - GlobeNewswire
Stempoint Capital LP Has $18.13 Million Stock Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Ally Bridge Group NY LLC Acquires 12,928 Shares of Praxis Precision Medicines, Inc. $PRAX - MarketBeat
Praxis Precision Medicines, Inc. $PRAX Position Trimmed by Exome Asset Management LLC - MarketBeat
Praxis Precision Medicines Inc (PRAX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
0.52%
0.07%
자본화:
|
볼륨(24시간):